Cingulate Therapeutics

On Thursday, major U.S. indices closed higher, with the Dow Jones Industrial Average increasing by 1.4% to 40,563.06, the S&P 500 rising 1.6% to 5,543.22, and the NASDAQ climbing 2.3% to 17,594.50. These are the top stocks that gained the attention of retail traders and investors throughout the...

Shane Schaffer, Chairman & CEO of Cingulate (NASDAQ: CING), and Tim Moore, Senior VP of Biotech of Indegene, were recently guests on Benzinga’s All Access. Cingulate is a biotechnology company that is developing drugs for a range of underserved conditions. The company has developed a...

Shane Schaffer, Chairman & CEO of Cingulate (NASDAQ: CING), was recently a guest on Benzinga’s All-Access. Cingulate is a clinical-stage biopharmaceutical company focused on the development of innovative new product candidates for the treatments of Attention Deficit/Hyperactivity Disorder...

Shane Schaffer, Chairman & CEO of Cingulate, Inc. (NASDAQ: CING), was a guest on Benzinga’s All Access on 12/16/22. Cingulate is a clinical-stage biopharmaceutical company focused on the development of innovative new product candidates for the treatments of Attention Deficit/...

Shane J. Schaffer and Dr. Ann Childress, CEO and consultant at Cingulate Inc. (NASDAQ: CING), respectively, were guest speakers at Benzinga’s All Access on June 3rd, 2022. Cingulate is a biopharmaceutical company engaging in the research and development of new product candidates for the...

This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice.  People diagnosed with attention-deficit/hyperactivity disorder (ADHD) have several options for treatment, but most of the medications available require...